Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab
Francesco Jacopo Romano(Federico II University Hospital), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Antonio Raucci, Paolo Maione(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gennaro Iengo(University of Naples Federico II), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Antonio Verde(University of Naples Federico II), Maria Rosaria Augurio(Federico II University Hospital), I Giacobbe(University of Campania "Luigi Vanvitelli"), Vito Longo(Istituto Tumori Bari), Giuseppe Failla(Azienda di Rilievo Nazionale ed Alta Specializzazione), Severo Campione(Federico II University Hospital), Marina Tarsitano(Ospedale Antonio Cardarelli), Riccardo Ronga(Ospedale Antonio Cardarelli), Dario Arundine(Ospedale Antonio Cardarelli), Vincenzo Damiano(University of Naples Federico II), Massimiliano Chetta(Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona), Francesca Ambrosio(Azienda Ospedaliero-Universitaria Careggi), Domenico Galetta(Istituto Tumori Bari)
Cited by 28
Related Papers
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234